GlassScriptPhysician profile
Sanjay Reddy
NPI 1619954393
$7,015.11
in general payments reported to CMS, 2019-2025
31 companies · $1,553 in 2025
The $1,553 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $328 · 2021: $639 · 2022: $907 · 2023: $1,001 · 2024: $1,981 · 2025: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,493 · Education: $42.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,493.22 |
| Education | $42.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,949.76 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $468.81 | 2021-2025 | Tremfya |
| Qol Medical, LLC | $457.55 | 2021-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $455.97 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $446.27 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $366.24 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $362.87 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $333.20 | 2024-2025 | Rezdiffra |
| Medtronic, INC. | $306.21 | 2021-2025 | Interstim |
| Phathom Pharmaceuticals, INC. | $295.78 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $249.93 | 2021-2022 | |
| Genzyme Corporation | $205.90 | 2022-2024 | |
| Celgene Corporation | $167.69 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $143.28 | 2024-2025 | Livdelzi |
| Celltrion USA INC. | $119.05 | 2023-2025 | Vegzelma, Yuflyma, Zymfentra |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $90.18 | 2019-2020 | |
| Lilly USA, LLC | $81.05 | 2024-2025 | Omvoh, Zepbound |
| Intercept Pharmaceuticals, INC. | $68.14 | 2020-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $56.22 | 2020-2024 | Rebyota |
| Redhill Biopharma INC. | $55.06 | 2020-2022 | |
| Amgen INC. | $52.26 | 2023 | Amjevita, Avsola |
| Ucb, INC. | $50.97 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.27 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $38.60 | 2024 | Dificid |
| Ardelyx, INC. | $33.71 | 2023 | Ibsrela |
| Braintree Laboratories, INC. | $32.33 | 2022-2023 | Sutab |
| Exact Sciences Corporation | $20.93 | 2023 | Cologuard Collection Kit |
| Enterra Medical, INC. | $19.68 | 2025 | |
| Capsovision, INC. | $17.80 | 2025 | Capsocam Plus |
| Ironwood Pharmaceuticals, INC | $17.56 | 2019 | |
| Ethicon US, LLC | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.